Announcements Trials
Browse Landscape

Phase

Phase 2 80Phase 1 40Phase 3 25Phase 1/2 12Phase EARLY_PHASE1 2Phase 2/3 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Oesophagogastric Cancer 1Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1Breast Diseases 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Lapatinib × Clear all
NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

RemeGen Co., Ltd.

Phase 2/3 Unknown
301 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03085368 2017-07-28

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Peking Union Medical College Hospital

Phase 2/3 Unknown
482 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡